Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation

KAZUKI MATSUMURA, KENSUKE YAMAMURA, HIDEAKI MIYAMOTO, YOSHIHIRO HARA, ERI ODA, SHINICHI AKAHOSHI, KENICHIRO YOSHIDA, HIDEAKI YUKI, TOSHIHIKO MOTOHARA, KATSUNORI SAKAMOTO, YOSHIHIRO KOMOHARA and TORU BEPPU
Anticancer Research March 2022, 42 (3) 1645-1651; DOI: https://doi.org/10.21873/anticanres.15641
KAZUKI MATSUMURA
1Department of Surgery, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENSUKE YAMAMURA
1Department of Surgery, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEAKI MIYAMOTO
2Department of Medical Oncology, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO HARA
1Department of Surgery, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ERI ODA
1Department of Surgery, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINICHI AKAHOSHI
1Department of Surgery, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENICHIRO YOSHIDA
3Department of Radiology, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEAKI YUKI
3Department of Radiology, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIHIKO MOTOHARA
4Department of Gastroenterology, Yamaga City Medical Center, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUNORI SAKAMOTO
5Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Toon, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOSHIHIRO KOMOHARA
6Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TORU BEPPU
1Department of Surgery, Yamaga City Medical Center, Yamaga, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tbeppu@yamaga-mc.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Fluorouracil plus leucovorin (5-FU/LV) is a less toxic but mild chemotherapy. Case Report: A 63-year-old male patient with rectal cancer and multiple colorectal liver metastases (CRLM, total volume of 1,826 ml) was hospitalized. He had several poor prognostic factors, including elevated levels of tumor markers, with carcinoembryonic antigen and carbohydrate antigen 19-9 levels of 17,119 ng/ml and 7,617 U/ml, respectively. Additionally, the patient had a low body mass index, poor performance status, and a history of apparent weight loss. After capecitabine and oxaliplatin for four cycles, 5-FU/LV has been lasting for nine months. Interestingly, tumor marker levels returned close to normal limits, and the total CRLM volume decreased to 154 ml without any enhancements. The patient’s general condition clearly improved after a year of chemotherapy. Conclusion: Chemotherapy with 5-FU/LV and percutaneous microwave ablation is beneficial to achieve tumor control in patients with highly advanced liver-only CRLM and poor general condition.

Key Words:
  • Colorectal liver metastases
  • fluorouracil plus leucovorin
  • microwave ablation
  • systemic chemotherapy

Systemic chemotherapy with cytotoxic and targeted agents is the standard therapy for patients with unresectable colorectal liver metastases (CRLM) (1-3). Patients must be first evaluated as fit or unfit for chemotherapy based on their medical conditions. The type and intensity of induction chemotherapy are selected depending on the purpose of cytoreduction or disease control. Moreover, primary tumor location and RAS/BRAF status are essential to determine therapeutic drugs. Conversion hepatectomy is recommended for patients who had initially unresectable CRLM that changed to resectable CRLM via induction chemotherapy (4-6). Conversion surgery using thermal ablation is an attractive option for small CRLM under optimal control of chemotherapy (7-9). Thermal ablation includes radiofrequency ablation (RFA) and microwave ablation (MWA).

Currently, fluorouracil plus leucovorin (5-FU/LV) monotherapy is administered only to CRLM patients determined unfit for oxaliplatin, irinotecan, and targeted agents (1-3, 10). The regimen is also sometimes used during the maintenance period of standard chemotherapy. A previous meta-analysis study has demonstrated that the median survival time was 12.7 months for patients treated with 5-FU/LV, and the performance status (PS) was the only independent predictor of overall survival (11).

Pretreatment levels of tumor markers are correlated with tumor volume and tumor activity (12-14). Carcinoembryonic antigen (CEA) is a well-known tumor marker for colorectal cancer and a prognostic factor of unresectable CRLM. Patients with CEA levels >100 ng/ml are candidates for a poor prognosis. CEA levels over 15,000 at the time of diagnosis are rarely observed in nationwide Japanese CRLM cohorts, with only 0.2% in 3,820 patients between 2005 and 2007 and 0.3% in 3,525 patients between 2013 and 2014 (15, 16). Similarly, high carbohydrate antigen 19-9 (CA 19-9) levels (>100 U/ml) has been reported as an independent factor of poor prognosis in upfront and rescue hepatic resection (17, 18). CA 19-9 positive cancer cells tend to adhere to cultured endothelial cells activated by some inflammatory cytokines, developing hematogenous metastasis (19).

Numerous prognostic factors in chemotherapy for unresectable CRLM include tumor, genetic, patient, and treatment factors (1-3, 6). Response to chemotherapy is a strong prognostic factor and is usually assessed by tumor regression and tumor necrosis as well as a decrease in tumor marker levels (20-22). The normalization of tumor marker levels after chemotherapy is a significant predictor of good recurrence-free and overall survival followed by hepatectomy (23). The half-life of CEA levels can predict the therapeutic effects of induction chemotherapy for CRLM (24).

In this study, we present a patient with highly advanced CRLM with rectal cancer that was successfully controlled with continuous mild systemic chemotherapy in combination with MWA.

Case Report

A 63-year-old male visited the referral hospital because of general fatigue and weight loss. He was sent to our hospital with a diagnosis of advanced rectal cancer with bilateral CRLM. Lower gastrointestinal endoscopy revealed a circumferential type 3 lesion, 8 cm in length in the rectosigmoid colon. Computed tomography (CT) showed a rectal lesion with a thickened wall with some swollen regional lymph nodes and numerous CRLM (>10 cm in diameter and >30 nodules) (Figure 1A-D). The total CRLM volume calculated by the Synapse VINCENT system (25) was 1,826 ml. The stage of rectal cancer was classified as stage IV [T4b, N1, M1(H3)] as per the 7th revision of the AJCC/UICC TNM staging system. The biopsy of the rectal lesion revealed moderately differentiated adenocarcinoma with p53 over-expression and increased Ki-67 labeling index (91%), CEA expression, and CA 19-9 expression (Figure 2). Gene analysis showed mutant-type RAS and wild-type BRAF genes. The patient had a low BMI (22.5), poor PS of Eastern Cooperative Oncology Group (ECOG) grade 2, and apparent weight loss (7.2 kg per year). His skeletal mass index was 43.6 cm2/m2 and was not classified into the sarcopenia criteria (<43 cm2/m2) but showed slightly decreased visceral fat amount (94.8 cm2/<103 cm2/) (26, 27). The laboratory data on admission showed an extremely high CEA level of 17,119 ng/ml (≤5 ng/ml) and a CA 19-9 level of 7,617 U/ml (≤39 U/ml). The primary rectal lesion showed severe stenosis; thus, a metallic stent was placed. Capecitabine and oxaliplatin (Cape OX) were started three days after stent placement. Following four cycles of Cape OX, the patient had severe diarrhea (grade 3) as per the 5th version of Common Terminology Criteria for Adverse Events due to capecitabine. Additionally, massive ascites appeared possibly due to veno-occlusive disease caused by oxaliplatin. Thus, chemotherapy was discontinued. Ascites was well controlled with diuretic drugs and two times of cell-free and concentrated ascites reinfusion therapy. Chemotherapy with 5-FU/LV was started after 40 days of discontinuation, mainly due to mild adverse events. About 8 months after starting treatment, contrast-enhanced CT revealed two CRLM with early enhancement; therefore, percutaneous MWA was performed twice. The recent enhanced CT showed excessively diminished CRLM with calcification (Figure 1E-H). The total CRLM volume evidently decreased to 154 ml. The dynamic magnetic resonance imaging (MRI) showed no enhancement of CRLM. The treatment course and tumor marker levels are listed in Figure 3. Surprisingly, CEA and CA 19-9 levels returned close to the standard limit (8.5 ng/ml and 12.7 U/ml, respectively). The half-lives of CEA levels were 15 days and 66 days during chemotherapy with Cape Ox and 5-FU/LV, respectively. The patient showed improvement of general condition without any viable lesions after one year of chemotherapy.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Pre-chemotherapy abdominal computed tomography (CT) images of liver tumors (A-D). A plain CT image showed multiple hypodense lesions with fine calcifications in the liver. Eight months after chemotherapy, contrast-enhanced CT images from the portal venous phase showed heavy calcification occupying metastases without enhancement (E-F). Additionally, the low-density area made by the microwave ablation (arrow) can be detected.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Histological analysis of biopsy specimen. Hematoxylin and eosin staining and immunohistochemistry of p53 (clone DO-7, DAKO, Glostrup, Denmark), Ki-67 (clone MIB-1, DAKO), CEA (clone II-7, DAKO), and CA 19-9 (clone 1116-NS-19-9, DAKO) are presented. Non-immune mouse IgG was used as negative control.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

The treatment course and changes in tumor marker levels. CEA: Carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; Cape OX: capecitabine and oxaliplatin; 5-FU/LV: fluorouracil + leucovorin; CART: cell-free and concentrated ascites reinfusion therapy; MWA: microwave ablation.

Discussion

Our patient showed liver-only metastases but had several poor clinical prognostic factors, including synchronous, large-sized, and multiple CRLM; lymph-node metastases of the primary lesion; and high levels of tumor markers (6, 14, 18, 21). Furthermore, positive p53 expression and high Ki-67 labeling index in the histochemical staining are independent unfavorable prognostic factors (28). CRLM patients with poor PS, low BMI, and preoperative weight loss are usually classified unfit for aggressive chemotherapy (1-3). One meta-analysis demonstrated that PS grade is the strongest predictor of survival in patients with metastatic colorectal cancer treated with 5-FU monotherapy and 5-FU/LV or 5-FU plus methotrexate (29). Median survival times were 14.6, 10.3, and 4.8 months for patients with ECOG grades 0, 1, and 2, respectively. A pooled analysis of five randomized trials of 5-FU-based chemotherapy showed that a low BMI (<25) was associated with a higher risk of hematologic toxicities (anemia and neutropenia) and poor overall survival patients with metastatic colorectal cancer compared with those with a high BMI (≥25) (30). Another study showed that >15% of weight loss six months before chemotherapy was significantly associated with short progression-free and overall survival (31). The current patient had a low BMI (22.5), poor PS (ECOG grade 2), and apparent weight loss (7.2 kg per year) at the start of chemotherapy.

Bevacizumab was not administered to our patient because of colorectal stenting. Standard Cape OX chemotherapy was discontinued after four cycles because of severe adverse events. After controlling diarrhea and massive ascites, 5-FU/LV monotherapy was started as palliative chemotherapy. The total volume of CRLM decreased from 1,826 ml to 429 ml after Cape OX therapy, which further decreased to 154 ml after 5-FU/LV monotherapy. Partial response according to the RECIST criteria has continued with no severe adverse events. Dynamic CT and MRI revealed that all CRLM had decreased in size and were accompanied by apparent calcification without any enhancement. Furthermore, no CRLM showed diffusion restriction in diffusion MRI. It was difficult to evaluate primary rectal cancer viability because of the metal stent, but no enlargement and enhancement was observed. Moreover, the exceptionally high pre-chemotherapeutic levels of CEA (17,119 ng/ml) and CA 19-9 (7,817 U/ml) were close to normalized by chemotherapy with 5-FU/LV followed by percutaneous MWA. We had reported that a shorter half-life (<20 days) is a predictor for good tumor response and pathological response (24). The half-life of our patient was 15 days through the Cape OX chemotherapy and 66 days through the 5 FU/LV. CRLM showed slight calcification pre-chemotherapy, and dense calcification developed with the increase in chemotherapy. Calcification of CRLM is detected among 12%-27% of patients with CRLM, and it is an independent good prognostic factor after chemotherapy (32). Tumor calcification during chemotherapy also predicts a high objective response rate and good overall survival (33).

For histopathological examination we only have a biopsy specimen of the primary colorectal tumor fixed to formalin. Therefore, it is difficult to resolve why a traditional 5-FU/LV is highly effective for the patient in our study. However, folypolyglutamated synthetase activity measured in CRLM tissue, which regulates thymidylate synthase, has been reported to be critical in assessing the responsiveness of 5-FU/LV (34). A previous study demonstrated that the protein expression of the 5-FU metabolic enzyme orotate phosphoribosyltransferase positively correlated with few adverse events and long patient survival of 5-FU-based chemotherapy (35). Furthermore, if resection of colorectal cancer and CRLM is possible, we may elucidate the reasons for the unexpected therapeutic effects.

The CLOCC study (EORTC 40004) was conducted as a randomized controlled phase II study comparing patients undergoing chemotherapy following RFA and those undergoing chemotherapy alone (36). Progression-free survival as a primary endpoint was significantly better in the chemotherapy plus RFA group compared with the chemotherapy alone group. Overall survival was comparable in the two groups; however, if the CRLM showed no progression during chemotherapy, overall survival of the chemotherapy plus RFA group was excellent and equivalent to that of the liver resection group in the EPOC trial (37). In our patient, the viable residual lesions were completely ablated with percutaneous MWA.

The observation period was too short to obtain conclusive results; however, we could show that the patient experienced excellent therapeutic effects despite multiple poor prognostic factors, including far-advanced CRLM status and poor general condition. Therefore, 5-FU/LV is still a promising option for selected patients with highly advanced but liver-only CRLM.

Footnotes

  • Authors’ Contributions

    KY, KM, and TB identified the concept and wrote the draft of the article. YK investigated pathological findings. All Authors treated the patient and collected data. All Authors read and approved the final version of the manuscript.

  • Conflicts of Interest

    The Authors have no conflicts of interest in relation to this study.

  • Received December 31, 2021.
  • Revision received January 17, 2022.
  • Accepted January 18, 2022.
  • Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

References

  1. ↵
    1. Yoshino T,
    2. Arnold D,
    3. Taniguchi H,
    4. Pentheroudakis G,
    5. Yamazaki K,
    6. Xu RH,
    7. Kim TW,
    8. Ismail F,
    9. Tan IB,
    10. Yeh KH,
    11. Grothey A,
    12. Zhang S,
    13. Ahn JB,
    14. Mastura MY,
    15. Chong D,
    16. Chen LT,
    17. Kopetz S,
    18. Eguchi-Nakajima T,
    19. Ebi H,
    20. Ohtsu A,
    21. Cervantes A,
    22. Muro K,
    23. Tabernero J,
    24. Minami H,
    25. Ciardiello F and
    26. Douillard JY
    : Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29(1): 44-70, 2018. PMID: 29155929. DOI: 10.1093/annonc/mdx738
    OpenUrlCrossRefPubMed
    1. Van Cutsem E,
    2. Cervantes A,
    3. Adam R,
    4. Sobrero A,
    5. Van Krieken JH,
    6. Aderka D,
    7. Aranda Aguilar E,
    8. Bardelli A,
    9. Benson A,
    10. Bodoky G,
    11. Ciardiello F,
    12. D’Hoore A,
    13. Diaz-Rubio E,
    14. Douillard JY,
    15. Ducreux M,
    16. Falcone A,
    17. Grothey A,
    18. Gruenberger T,
    19. Haustermans K,
    20. Heinemann V,
    21. Hoff P,
    22. Köhne CH,
    23. Labianca R,
    24. Laurent-Puig P,
    25. Ma B,
    26. Maughan T,
    27. Muro K,
    28. Normanno N,
    29. Österlund P,
    30. Oyen WJ,
    31. Papamichael D,
    32. Pentheroudakis G,
    33. Pfeiffer P,
    34. Price TJ,
    35. Punt C,
    36. Ricke J,
    37. Roth A,
    38. Salazar R,
    39. Scheithauer W,
    40. Schmoll HJ,
    41. Tabernero J,
    42. Taïeb J,
    43. Tejpar S,
    44. Wasan H,
    45. Yoshino T,
    46. Zaanan A and
    47. Arnold D
    : ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8): 1386-1422, 2016. PMID: 27380959. DOI: 10.1093/annonc/mdw235
    OpenUrlCrossRefPubMed
  2. ↵
    1. Watanabe T,
    2. Muro K,
    3. Ajioka Y,
    4. Hashiguchi Y,
    5. Ito Y,
    6. Saito Y,
    7. Hamaguchi T,
    8. Ishida H,
    9. Ishiguro M,
    10. Ishihara S,
    11. Kanemitsu Y,
    12. Kawano H,
    13. Kinugasa Y,
    14. Kokudo N,
    15. Murofushi K,
    16. Nakajima T,
    17. Oka S,
    18. Sakai Y,
    19. Tsuji A,
    20. Uehara K,
    21. Ueno H,
    22. Yamazaki K,
    23. Yoshida M,
    24. Yoshino T,
    25. Boku N,
    26. Fujimori T,
    27. Itabashi M,
    28. Koinuma N,
    29. Morita T,
    30. Nishimura G,
    31. Sakata Y,
    32. Shimada Y,
    33. Takahashi K,
    34. Tanaka S,
    35. Tsuruta O,
    36. Yamaguchi T,
    37. Yamaguchi N,
    38. Tanaka T,
    39. Kotake K,
    40. Sugihara K and Japanese Society for Cancer of the Colon and Rectum
    : Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol 23(1): 1-34, 2018. PMID: 28349281. DOI: 10.1007/s10147-017-1101-6
    OpenUrlCrossRefPubMed
  3. ↵
    1. Adam R,
    2. De Gramont A,
    3. Figueras J,
    4. Guthrie A,
    5. Kokudo N,
    6. Kunstlinger F,
    7. Loyer E,
    8. Poston G,
    9. Rougier P,
    10. Rubbia-Brandt L,
    11. Sobrero A,
    12. Tabernero J,
    13. Teh C,
    14. Van Cutsem E and Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group
    : The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17(10): 1225-1239, 2012. PMID: 22962059. DOI: 10.1634/theoncologist.2012-0121
    OpenUrlAbstract/FREE Full Text
    1. van der Geest LG,
    2. Lam-Boer J,
    3. Koopman M,
    4. Verhoef C,
    5. Elferink MA and
    6. de Wilt JH
    : Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis 32(5): 457-465, 2015. PMID: 25899064. DOI: 10.1007/s10585-015-9719-0
    OpenUrlCrossRefPubMed
  4. ↵
    1. Beppu T,
    2. Miyamoto Y,
    3. Sakamoto Y,
    4. Imai K,
    5. Nitta H,
    6. Hayashi H,
    7. Chikamoto A,
    8. Watanabe M,
    9. Ishiko T and
    10. Baba H
    : Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol 21 Suppl 3: S405-S413, 2014. PMID: 24570379. DOI: 10.1245/s10434-014-3577-x
    OpenUrlCrossRefPubMed
  5. ↵
    1. Mima K,
    2. Beppu T,
    3. Chikamoto A,
    4. Miyamoto Y,
    5. Nakagawa S,
    6. Kuroki H,
    7. Okabe H,
    8. Hayashi H,
    9. Sakamoto Y,
    10. Watanabe M,
    11. Kikuchi K and
    12. Baba H
    : Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. Int J Clin Oncol 18(5): 847-855, 2013. PMID: 22940848. DOI: 10.1007/s10147-012-0471-z
    OpenUrlCrossRefPubMed
    1. Gillams A,
    2. Goldberg N,
    3. Ahmed M,
    4. Bale R,
    5. Breen D,
    6. Callstrom M,
    7. Chen MH,
    8. Choi BI,
    9. de Baere T,
    10. Dupuy D,
    11. Gangi A,
    12. Gervais D,
    13. Helmberger T,
    14. Jung EM,
    15. Lee F,
    16. Lencioni R,
    17. Liang P,
    18. Livraghi T,
    19. Lu D,
    20. Meloni F,
    21. Pereira P,
    22. Piscaglia F,
    23. Rhim H,
    24. Salem R,
    25. Sofocleous C,
    26. Solomon SB,
    27. Soulen M,
    28. Tanaka M,
    29. Vogl T,
    30. Wood B and
    31. Solbiati L
    : Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013. Eur Radiol 25(12): 3438-3454, 2015. PMID: 25994193. DOI: 10.1007/s00330-015-3779-z
    OpenUrlCrossRefPubMed
  6. ↵
    1. Imai K,
    2. Allard MA,
    3. Castro Benitez C,
    4. Vibert E,
    5. Sa Cunha A,
    6. Cherqui D,
    7. Castaing D,
    8. Baba H and
    9. Adam R
    : Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg 104(5): 570-579, 2017. PMID: 28112813. DOI: 10.1002/bjs.10447
    OpenUrlCrossRefPubMed
  7. ↵
    1. Cremolini C,
    2. Casagrande M,
    3. Loupakis F,
    4. Aprile G,
    5. Bergamo F,
    6. Masi G,
    7. Moretto R R,
    8. Pietrantonio F,
    9. Marmorino F,
    10. Zucchelli G,
    11. Tomasello G,
    12. Tonini G,
    13. Allegrini G,
    14. Granetto C,
    15. Ferrari L,
    16. Urbani L,
    17. Cillo U,
    18. Pilati P,
    19. Sensi E,
    20. Pellegrinelli A,
    21. Milione M,
    22. Fontanini G and
    23. Falcone A
    : Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. Eur J Cancer 73: 74-84, 2017. PMID: 27986363. DOI: 10.1016/j.ejca.2016.10.028
    OpenUrlCrossRefPubMed
  8. ↵
    1. Thirion P,
    2. Wolmark N,
    3. Haddad E,
    4. Buyse M and
    5. Piedbois P
    : Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol 10(11): 1317-1320, 1999. PMID: 10631459. DOI: 10.1023/a:1008365511961
    OpenUrlCrossRefPubMed
  9. ↵
    1. Wang WS,
    2. Lin JK,
    3. Lin TC,
    4. Chiou TJ,
    5. Liu JH,
    6. Fan FS,
    7. Yen CC,
    8. Chen WS,
    9. Jiang JK,
    10. Yang SH,
    11. Wang HS and
    12. Chen PM
    : Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer. Int J Colorectal Dis 16(2): 96-101, 2001. PMID: 11355325. DOI: 10.1007/s003840000266
    OpenUrlCrossRefPubMed
    1. Goldstein MJ and
    2. Mitchell EP
    : Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 23(4): 338-351, 2005. PMID: 16100946. DOI: 10.1081/cnv-58878
    OpenUrlCrossRefPubMed
  10. ↵
    1. Mitsuyama Y,
    2. Shiba H,
    3. Haruki K,
    4. Fujiwara Y,
    5. Furukawa K,
    6. Iida T,
    7. Hayashi T,
    8. Ogawa M,
    9. Ishida Y,
    10. Misawa T,
    11. Kashiwagi H and
    12. Yanaga K
    : Carcinoembryonic antigen and carbohydrate antigen 19-9 are prognostic predictors of colorectal cancer with unresectable liver metastasis. Oncol Lett 3(4): 767-771, 2012. PMID: 22740990. DOI: 10.3892/ol.2012.574
    OpenUrlCrossRefPubMed
  11. ↵
    1. Sakamoto K,
    2. Honda G,
    3. Beppu T,
    4. Kotake K,
    5. Yamamoto M,
    6. Takahashi K,
    7. Endo I,
    8. Hasegawa K,
    9. Itabashi M,
    10. Hashiguchi Y,
    11. Kotera Y,
    12. Kobayashi S,
    13. Yamaguchi T,
    14. Morita S,
    15. Miyazaki M,
    16. Sugihara K and Joint Committee for Nationwide Survey on Colorectal Liver Metastasis
    : Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan. J Hepatobiliary Pancreat Sci 25(2): 115-123, 2018. PMID: 28990311. DOI: 10.1002/jhbp.510
    OpenUrlCrossRefPubMed
  12. ↵
    1. Sakamoto K,
    2. Honda G,
    3. Beppu T,
    4. Kotake K,
    5. Yamamoto M,
    6. Takahashi K,
    7. Endo I,
    8. Hasegawa K,
    9. Itabashi M,
    10. Hashiguchi Y,
    11. Kotera Y,
    12. Kobayashi S,
    13. Yamaguchi T,
    14. Tabuchi K,
    15. Kobayashi H,
    16. Yamaguchi K,
    17. Morita S,
    18. Miyazaki M and
    19. Sugihara K
    : Comprehensive data of 3525 patients newly diagnosed with colorectal liver metastasis between 2013 and 2014: 2nd report of a nationwide survey in Japan. J Hepatobiliary Pancreat Sci 27(8): 555-562, 2020. PMID: 32281742. DOI: 10.1002/jhbp.738
    OpenUrlCrossRefPubMed
  13. ↵
    1. Adam R,
    2. Delvart V,
    3. Pascal G,
    4. Valeanu A,
    5. Castaing D,
    6. Azoulay D,
    7. Giacchetti S,
    8. Paule B,
    9. Kunstlinger F,
    10. Ghémard O,
    11. Levi F and
    12. Bismuth H
    : Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240(4): 644-57; discussion 657-8, 2004. PMID: 15383792. DOI: 10.1097/01.sla.0000141198.92114.f6
    OpenUrlCrossRefPubMed
  14. ↵
    1. Beppu T,
    2. Sakamoto Y,
    3. Hasegawa K,
    4. Honda G,
    5. Tanaka K,
    6. Kotera Y,
    7. Nitta H,
    8. Yoshidome H,
    9. Hatano E,
    10. Ueno M,
    11. Takamura H,
    12. Baba H,
    13. Kosuge T,
    14. Kokudo N,
    15. Takahashi K,
    16. Endo I,
    17. Wakabayashi G,
    18. Miyazaki M,
    19. Uemoto S,
    20. Ohta T,
    21. Kikuchi K,
    22. Yamaue H,
    23. Yamamoto M and
    24. Takada T
    : A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 19(1): 72-84, 2012. PMID: 22020927. DOI: 10.1007/s00534-011-0460-z
    OpenUrlCrossRefPubMed
  15. ↵
    1. Nakagoe T,
    2. Sawai T,
    3. Tsuji T,
    4. Jibiki MA,
    5. Nanashima A,
    6. Yamaguchi H,
    7. Yasutake T,
    8. Ayabe H,
    9. Arisawa K and
    10. Ishikawa H
    : Difference in prognostic value between sialyl Lewis(a) and sialyl Lewis(x) antigen levels in the preoperative serum of gastric cancer patients. J Clin Gastroenterol 34(4): 408-415, 2002. PMID: 11907351. DOI: 10.1097/00004836-200204000-00005
    OpenUrlCrossRefPubMed
  16. ↵
    1. Adam R,
    2. de Gramont A,
    3. Figueras J,
    4. Kokudo N,
    5. Kunstlinger F,
    6. Loyer E,
    7. Poston G,
    8. Rougier P,
    9. Rubbia-Brandt L,
    10. Sobrero A,
    11. Teh C,
    12. Tejpar S,
    13. Van Cutsem E,
    14. Vauthey JN,
    15. Påhlman L and of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group
    : Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev 41(9): 729-741, 2015. PMID: 26417845. DOI: 10.1016/j.ctrv.2015.06.006
    OpenUrlCrossRefPubMed
  17. ↵
    1. Rehman AH,
    2. Jones RP and
    3. Poston G
    : Prognostic and predictive markers in liver limited stage IV colorectal cancer. Eur J Surg Oncol 45(12): 2251-2256, 2019. PMID: 31279594. DOI: 10.1016/j.ejso.2019.06.038
    OpenUrlCrossRefPubMed
  18. ↵
    1. de Haas RJ,
    2. Wicherts DA,
    3. Flores E,
    4. Ducreux M,
    5. Lévi F,
    6. Paule B,
    7. Azoulay D,
    8. Castaing D,
    9. Lemoine A and
    10. Adam R
    : Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases. Ann Surg Oncol 17(4): 1010-1023, 2010. PMID: 20052553. DOI: 10.1245/s10434-009-0887-5
    OpenUrlCrossRefPubMed
  19. ↵
    1. Sakamoto Y,
    2. Miyamoto Y,
    3. Beppu T,
    4. Nitta H,
    5. Imai K,
    6. Hayashi H,
    7. Baba Y,
    8. Yoshida N,
    9. Chikamoto A and
    10. Baba H
    : Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy. Anticancer Res 35(4): 2359-2368, 2015. PMID: 25862901.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Nagai Y,
    2. Beppu T,
    3. Sakamoto Y,
    4. Miyamoto Y,
    5. Hayashi H,
    6. Nitta H,
    7. Imai K,
    8. Masuda T,
    9. Okabe H,
    10. Hirashima K,
    11. Imamura Y,
    12. Baba Y,
    13. Chikamoto A and
    14. Baba H
    : Carcinoembryonic antigen half-life is an early predictor of therapeutic effects in induction chemotherapy for liver metastases from colorectal cancer. Anticancer Res 34(10): 5529-5535, 2014. PMID: 25275051.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Ohshima S
    : Volume analyzer SYNAPSE VINCENT for liver analysis. J Hepatobiliary Pancreat Sci 21(4): 235-238, 2014. PMID: 24520049. DOI: 10.1002/jhbp.81
    OpenUrlCrossRefPubMed
  22. ↵
    1. Mourtzakis M,
    2. Prado CM,
    3. Lieffers JR,
    4. Reiman T,
    5. McCargar LJ and
    6. Baracos VE
    : A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33(5): 997-1006, 2008. PMID: 18923576. DOI: 10.1139/H08-075
    OpenUrlCrossRefPubMed
  23. ↵
    1. Kashihara H,
    2. Lee JS,
    3. Kawakubo K,
    4. Tamura M and
    5. Akabayashi A
    : Criteria of waist circumference according to computed tomography-measured visceral fat area and the clustering of cardiovascular risk factors. Circ J 73(10): 1881-1886, 2009. PMID: 19652399. DOI: 10.1253/circj.cj-09-0183
    OpenUrlCrossRefPubMed
  24. ↵
    1. Wang L,
    2. Liu Z,
    3. Fisher KW,
    4. Ren F,
    5. Lv J,
    6. Davidson DD,
    7. Baldridge LA,
    8. Du X and
    9. Cheng L
    : Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer. Hum Pathol 71: 20-29, 2018. PMID: 28782638. DOI: 10.1016/j.humpath.2017.07.014
    OpenUrlCrossRefPubMed
  25. ↵
    1. Thirion P,
    2. Wolmark N,
    3. Haddad E,
    4. Buyse M and
    5. Piedbois P
    : Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer. Ann Oncol 10(11): 1317-1320, 1999. PMID: 10631459. DOI: 10.1023/a:1008365511961
    OpenUrlCrossRefPubMed
  26. ↵
    1. Abdel-Rahman O
    : Effect of body mass index on 5-FU-based chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer; a pooled analysis of 5 randomized trials. Clin Colorectal Cancer 18(4): e385-e393, 2019. PMID: 31378656. DOI: 10.1016/j.clcc.2019.07.005
    OpenUrlCrossRefPubMed
  27. ↵
    1. Guercio BJ,
    2. Zhang S,
    3. Venook AP,
    4. Ou FS,
    5. Niedzwiecki D,
    6. Lenz HJ,
    7. Innocenti F,
    8. Mullen BC,
    9. O’Neil BH,
    10. Shaw JE,
    11. Polite BN,
    12. Hochster HS,
    13. Atkins JN,
    14. Goldberg RM,
    15. Brown JC,
    16. O’Reilly EM,
    17. Mayer RJ,
    18. Blanke CD,
    19. Fuchs CS and
    20. Meyerhardt JA
    : Body mass index and weight loss in metastatic colorectal cancer in CALGB (Alliance)/SWOG 80405. JNCI Cancer Spectr 4(3): pkaa024, 2020. PMID: 33134818. DOI: 10.1093/jncics/pkaa024
    OpenUrlCrossRefPubMed
  28. ↵
    1. Easson AM,
    2. Barron PT,
    3. Cripps C,
    4. Hill G,
    5. Guindi M and
    6. Michaud C
    : Calcification in colorectal hepatic metastases correlates with longer survival. J Surg Oncol 63(4): 221-225, 1996. PMID: 8982365. DOI: 10.1002/(SICI)1096-9098(199612)63:4<221::AID-JSO2>3.0.CO;2-E
    OpenUrlCrossRefPubMed
  29. ↵
    1. Zhou Y,
    2. Zhang J,
    3. Dan Pu, Bi F,
    4. Chen Y,
    5. Liu J,
    6. Li Q,
    7. Gou H,
    8. Wu B and
    9. Qiu M
    : Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer. Anticancer Drugs 30(2): 195-200, 2019. PMID: 30570508. DOI: 10.1097/CAD.0000000000000726
    OpenUrlCrossRefPubMed
  30. ↵
    1. Chazal M,
    2. Cheradame S,
    3. Formento JL,
    4. Francoual M,
    5. Formento P,
    6. Etienne MC,
    7. François E,
    8. Richelme H,
    9. Mousseau M,
    10. Letoublon C,
    11. Pezet D,
    12. Cure H,
    13. Seitz JF and
    14. Milano G
    : Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. Clin Cancer Res 3(4): 553-557, 1997. PMID: 9815719.
    OpenUrlAbstract
  31. ↵
    1. Komori S,
    2. Osada S,
    3. Tomita H,
    4. Nishio K,
    5. Kumazawa I,
    6. Tachibana S,
    7. Tsuchiya J and
    8. Yoshida K
    : Predictive value of orotate phosphoribosyltransferase in colorectal cancer patients receiving 5-FU-based chemotherapy. Mol Clin Oncol 1(3): 453-460, 2013. PMID: 24649191. DOI: 10.3892/mco.2013.71
    OpenUrlCrossRefPubMed
  32. ↵
    1. Ruers T,
    2. Punt C,
    3. Van Coevorden F,
    4. Pierie JPEN,
    5. Borel-Rinkes I,
    6. Ledermann JA,
    7. Poston G,
    8. Bechstein W,
    9. Lentz MA,
    10. Mauer M,
    11. Van Cutsem E,
    12. Lutz MP,
    13. Nordlinger B, EORTC Gastro-Intestinal Tract Cancer Group and Arbeitsgruppe Lebermetastasen und—tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO) and the National Cancer Research Institute Colorectal Clinical Study Group (NCRI CCSG)
    : Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23(10): 2619-2626, 2012. PMID: 22431703. DOI: 10.1093/annonc/mds053
    OpenUrlCrossRefPubMed
  33. ↵
    1. Tanis E,
    2. Nordlinger B,
    3. Mauer M,
    4. Sorbye H,
    5. van Coevorden F,
    6. Gruenberger T,
    7. Schlag PM,
    8. Punt CJ,
    9. Ledermann J and
    10. Ruers TJ
    : Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 50(5): 912-919, 2014. PMID: 24411080. DOI: 10.1016/j.ejca.2013.12.008
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (3)
Anticancer Research
Vol. 42, Issue 3
March 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
17 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation
KAZUKI MATSUMURA, KENSUKE YAMAMURA, HIDEAKI MIYAMOTO, YOSHIHIRO HARA, ERI ODA, SHINICHI AKAHOSHI, KENICHIRO YOSHIDA, HIDEAKI YUKI, TOSHIHIKO MOTOHARA, KATSUNORI SAKAMOTO, YOSHIHIRO KOMOHARA, TORU BEPPU
Anticancer Research Mar 2022, 42 (3) 1645-1651; DOI: 10.21873/anticanres.15641

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation
KAZUKI MATSUMURA, KENSUKE YAMAMURA, HIDEAKI MIYAMOTO, YOSHIHIRO HARA, ERI ODA, SHINICHI AKAHOSHI, KENICHIRO YOSHIDA, HIDEAKI YUKI, TOSHIHIKO MOTOHARA, KATSUNORI SAKAMOTO, YOSHIHIRO KOMOHARA, TORU BEPPU
Anticancer Research Mar 2022, 42 (3) 1645-1651; DOI: 10.21873/anticanres.15641
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Case Report
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases
  • Google Scholar

More in this TOC Section

  • Tumor Budding Grade and T Stage as Recurrence Predictors of High-risk Stage II Colorectal Cancer
  • Pathologic Complete Response (pCR) in Patient With Myxofibrosarcoma Who Underwent Neoadjuvant Radiation Concurrent to Complementary and Alternative Medicine
  • Machine Learning Model to Guide Empirical Antimicrobial Therapy in Febrile Neutropenic Patients With Hematologic Malignancies
Show more Clinical Studies

Similar Articles

Keywords

  • colorectal liver metastases
  • fluorouracil plus leucovorin
  • microwave ablation
  • systemic chemotherapy
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire